Trump's Chinese Import Tariff Hike Could Take Toll On Consumer Health Sector
Executive Summary
Low margins, limited supplier alternatives leave little room for OTC drug marketers in the US to maneuver as ingredients continue to be subject to Chinese import tariffs.
You may also be interested in...
Proposed Tariffs Threaten Ingredient Supply Chain For US Supplement Firms
NPA sounds alarm on Trump administration tariffs on $200bn in Chinese goods scheduled for October. In letter US Trade Representative, NPA President and CEO Daniel Fabricant asks the agency to exempt 57 items from the Harmonized Tariff Schedule that would impact hundreds of dietary ingredients.
Industry Urged To Watch And Wait For US/China Tariff War To Blow Over
Don’t do anything rash to avoid US tariffs on drug products, ingredients and supplies from China, consultants advise. It would be better to just wait to see if the tariff war blows over.
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.